Trial Profile
An Evaluation of Treatment With Omalizumab to Improve the Asthmatic Response to an Experimental Infection With Rhinovirus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms Anti-IgE study
- 01 Feb 2020 Results (n=20) published in the Journal of Allergy and Clinical Immunology
- 02 Jul 2018 Status changed from active, no longer recruiting to completed.
- 19 Apr 2018 Planned End Date changed from 1 Jun 2017 to 30 Jun 2018.